Depletion of METTL3 expression can further impede tumorigenicity and heighten the sensitivity of lung cancer cells to BRD4 inhibition, implicating METTL3 as a viable candidate for cancer therapeutics.123. The gene discussed is METTL3; the disease is cancer.